论文部分内容阅读
目的探讨新辅助化疗联合手术与单纯手术治疗食管癌的临床疗效。方法将2013年9月至2014年9月胸外科符合入选标准的受试者100例作为研究对象。将所有患者按照随机分配原则分为对照组和试验组,对照组患者行单纯手术治疗,试验组患者行新辅助化疗联合手术治疗。比较两组患者的生存率、生活质量改善情况以及术后复发情况。结果试验组患者在生存率、生活质量改善以及术后复发情况均优于对照组,差异均有统计学意义(均P<0.05)。结论对于食管癌患者,新辅助化疗联合手术治疗的临床治疗效果比单纯手术治疗效果更好。
Objective To investigate the clinical efficacy of neoadjuvant chemotherapy combined with surgery and simple surgery in the treatment of esophageal cancer. Methods From September 2013 to September 2014, 100 patients who met the inclusion criteria of thoracic surgery were enrolled in this study. According to the principle of random distribution, all patients were divided into control group and experimental group. Patients in control group were treated with simple surgery. Patients in experimental group were treated with neoadjuvant chemotherapy combined with surgery. Survival rates, quality of life improvement, and postoperative recurrence were compared between the two groups. Results The survival rate, quality of life and postoperative recurrence in the experimental group were better than those in the control group (all P <0.05). Conclusion For patients with esophageal cancer, neoadjuvant chemotherapy combined with surgical treatment of clinical effect than simple surgical treatment better.